Article Abstract

Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant

Authors: Valerie Nelson, Alfred Rademaker, Virginia Kaklamani

Abstract

Endocrine therapy is the cornerstone of any treatment plan for endocrine-responsive breast cancer in both the adjuvant and metastatic settings (1). In the metastatic setting in post-menopausal patients aromatase inhibitors (AIs; anastrozole, exemestane, letrozole) are standard therapies, shown to demonstrate improved progression-free survival (PFS) and a favorable adverse effect (AE) profile compared to other endocrine agents such as tamoxifen (2,3).

Refbacks

  • There are currently no refbacks.